ArticleScientific reports2026
Modulatory effects of valproic acid and UGT polymorphisms on norclozapine plasma levels in clozapine-treated patients with schizophrenia.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucuronidation, catalysed by UGT enzymes, plays a key role in the metabolism of clozapine (CLZ) and its active metabolite, norclozapine (NCLZ). Genetic polymorphisms in UGT1A4 and UGT2B10 can influence NCLZ plasma levels. Co-administration of valproic acid (VPA), commonly used in Treatment Resistant Schizophrenia, has been linked to decreased NCLZ concentrations and increased neutropenia risk. Additionally, CYP1A2, the main enzyme responsible for CLZ N-demethylation, may affect CLZ and indirectly NCLZ levels, specially considering genetic variability and smoking status. A total of 296 plasma samples from 61 CLZ-treated patients were retrospectively analysed. CLZ and NCLZ levels were quantified using Liquid Chromatography-Tandem masses (LC-MS/MS). VPA levels were measured by Ultraviolet–Visible spectrophotometric immunoassay. Genotyping for CYP1A2*1F (rs762551) and UGT2B10*2 (rs61750900) polymorphisms was performed using Real-Time PCR and UGT1A4*3 (rs2011425) polymorphism was conducted through direct sequencing. VPA co-administration significantly reduced NCLZ levels (–49.20%, p < 0.001) with minimal impact on CLZ. CYP1A2*1F/*1F and UGT1A4*1/*3 or *3/3 were associated with lower NCLZ levels and dose-adjusted ratios (C/D). These associations were not significant in the VPA group. Absolute neutrophil count (ANC) was 15.96% lower in VPA co-treated patients (p < 0.001) and positively correlated with NCLZ levels. These results emphasize the importance of integrating pharmacogenetic and pharmacokinetic data when prescribing VPA and CLZ concomitantly, to optimize therapeutic efficacy and minimize adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.